Ann: NTCELL Parkinsons trial patient data 2 years after implant, page-63

Questions for my statistically challenged benefit.

Q1 Once the 6 mth trial became unblinded, did the placebo effect cease to be measured?

Q2. Why are new patients needed for control? Isn’t the entire population of PD pts or a random sample therefrom a control?

Q3. What about the nocebo effect? Pts who are informed of having had placebo are still subject to the nocebo effect, ie I don’t care it was a sham, I feel a benefit and will continue to release dopamine as a result.

Q4. How can any result be deemed significant one day (at 18mths) and not the next? Can the null hypothesis be so elastic?

Thx in advance for anyone willing to waste their time as I’ve just done.
u